| Description | MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells. |
| In vitro | CLL cells were incubated with increasing concentrations of MP07-66 (0-16 μM) for 24 and 48 hours and then subject to annexin V–PI flow cytometry. The level of apoptosis reached 50% and 80%, at 24 hours and 48 hours, respectively, at a MP07-66 concentration as high as 16 μM, which paralleled PARP cleavage, a marker of caspase-dependent apoptosis. In addition, the phosphorylation status of PP2A targets, namely Akt, GSK-3, and SHP-1, was negatively affected by the treatment with MP07-66, triggering known downstream events promoting apoptosis, such as Mcl-1 degradation and caspase-3 activation[1]. |
| molecular weight | 323.47 |
| Molecular formula | C19H33NO3 |
| CAS | 1938056-90-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 250 mg/mL (772.87 mM) |
| References | 1. Zonta F, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood. 2015;125(24):3747-3755. |